About 100 reports

  • BLOOD DISEASE DRUGS
  • BLOOD DISEASE DRUGS PRODUCER DIRECTORY

This study focuses on China’s Blood Disease Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China...

  • Blood Disease
  • China
  • Eisai Co., Ltd.
  • Roche Pharmaceutical Co., Ltd
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd
  • BLOOD DISEASE DRUGS
  • Blood Disease Drugs Sales Volume

China’s demand for Blood Disease Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer...

  • Blood Disease
  • China
  • Demand
  • Eisai Co., Ltd.
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd
  • Other Blood Disease Drugs
  • Other Blood Disease Drugs

This study focuses on China’s Blood Disease Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s...

  • Blood Disease
  • China
  • Trade
  • Lijun Pharmaceutical Co., Ltd.
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd

The report features 2017 current and 2018 forecast estimates on the sales of Patient care - Blood diseases sold through Medical & surgical hospitals nationally and for all ## U. S.

  • Blood Disease
  • Pathology
  • United States
  • Demand

The report features 2017 current and 2018 forecast estimates on the sales of Patient care - Blood diseases sold through Offices of physicians nationally and for all ## U. S.

  • Blood Disease
  • Pathology
  • United States
  • Demand
  • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
  • The content of this press release is solely the views of its authors and does not represent the official views of the National Institutes of Health.

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Pipeline Review, H2 2017 Summary According to the recently published report ’Hepcidin - Pipeline Review, H2 2017’; Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) pipeline Target...

  • Blood Disease
  • Turkey
  • United States
  • World
  • Product Initiative

AFTER DONATION, EACH UNIT OF DONATED BLOOD IS REQUIRED TO UNDERGO A SERIES OF TESTS FOR INFECTIOUS DISEASES, INCLUDING: ##.

  • Blood Disease
  • World
  • Baxter International Inc.
  • Biotest AG
  • CSL Limited
  • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
  • Dec 05, 2017: Italfarmaco Announces Givinostat Clinical Trial Presentations at the 59th American Society of Hematology (ASH) Annual Meeting

Polycythemia Vera - Pipeline Review, H2 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Polycythemia Vera - Pipeline Review, H2 2018, provides an overview of the Polycythemia Vera (Oncology) pipeline landscape. Polycythemia Vera (PV) is a stem...

  • Blood Disease
  • Pathology
  • Therapy
  • United States
  • Product Initiative
  • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
  • Dec 05, 2017: Italfarmaco Announces Givinostat Clinical Trial Presentations at the 59th American Society of Hematology (ASH) Annual Meeting

Polycythemia Vera - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Polycythemia Vera - Pipeline Review, H1 2018, provides an overview of the Polycythemia Vera (Oncology) pipeline landscape. Polycythemia Vera (PV) is a stem...

  • Blood Disease
  • Pathology
  • Therapy
  • United States
  • Product Initiative
  • Global Acquired Orphan Blood Diseases Therapeutics Market
  • Global Acquired Orphan Blood Diseases Therapeutics Market

About Acquired Orphan Blood Diseases Therapeutics Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can...

  • Blood Disease
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.

Additional Areas in Sickle Cell Disease Date and Time: Thursday, October ##, 2017, ##:##-##:## p. m.

  • Blood Disease
  • Therapy
  • World
  • Company Operations
  • Roche Group
  • Fanconi Anemia - Drug Profiles
  • Fanconi Anemia - Companies Involved in Therapeutics Development

Fanconi Anemia - Pipeline Review, H2 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Fanconi Anemia - Pipeline Review, H2 2018, provides an overview of the Fanconi Anemia (Hematological Disorders) pipeline landscape. Fanconi anemia (fan-KO-nee...

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • GlaxoSmithKline plc
  • BIOMARKER ASSAY - SEPSIS - PRODUCT DESCRIPTION

Liquid biopsy: Detection of cancer or other diseases by testing bodily fluids such as blood.

  • Blood Disease
  • Clinical Trial
  • CT Scan
  • Medical Device
  • Grifols, S.A.
  • Hematology Drugs Market Historic Growth

Hematology drugs market offers drugs, blood and blood products that are used for the treatment of diseases such as rare genetic disorders, anemia, and conditions related to sickle cell disease and other related diseases.

  • Blood Disease
  • World
  • Bayer AG
  • Novo Nordisk Group
  • Shire plc
  • DIAGNOSTIC TEST - HEMOPHILIA - PRODUCT DESCRIPTION
  • RAPID QUANTITATIVE HEPARIN-INDUCED THROMBOCYTOPENIA (H.I.T.) TEST - PRODUCT DESCRIPTION

From ## of these players, blood samples were taken ##, ##, ## and ## hours (six days) after the concussion.

  • Blood Disease
  • Clinical Trial
  • In Vitro Diagnostics
  • Point Of Care Testing
  • Siemens Healthcare GmbH

PV and ET, along with myelofibrosis (MF), are blood cancers that belong to a group of diseases known as myeloproliferative neoplasms (MPNs).

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Incyte Corporation
  • Dec 04, 2017: La Jolla Pharmaceutical Company Announces Initiation of Pivotal Clinical Study of LJPC-401 in Patients With Beta Thalassemia
  • SMALL MOLECULES TO INHIBIT PRMT5 FOR HAEMOGLOBINOPATHIES AND SOLID TUMOURS - DRUG PROFILE

VCN in peripheral blood was ##. ##copies/ genome at ## month after LentiGlobin infusion.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Incyte Corporation
  • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
  • M-009 - Drug Profile

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Pipeline Review, H1 2017 Summary Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Hepcidin is a protein encoded by the HAMP gene. It acts by promoting endocytosis and degradation...

  • Blood Disease
  • Therapy
  • Turkey
  • United States
  • Product Initiative
  • Fanconi Anemia - Drug Profiles
  • Fanconi Anemia - Companies Involved in Therapeutics Development

Fanconi Anemia - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Fanconi Anemia - Pipeline Review, H1 2018, provides an overview of the Fanconi Anemia (Hematological Disorders) pipeline landscape. Fanconi anemia (fan-KO-nee...

  • Blood Disease
  • Therapy
  • United States
  • World
  • Product Initiative

Sickle cell disease is a debilitating genetic disorder that causes red blood cells to become sickle-shaped, reducing normal red blood cell number, blood flow and oxygen delivery to organs.

  • Blood Disease
  • Hospital
  • Pharmaceutical
  • Therapy
  • NicOx S.A.
  • Featured News & Press Releases

An investigational treatment that mimics a key clotting enzyme is effective, safe, and may one day eliminate the need for blood products for people with the rare, life-threatening blood disease hereditary thrombotic thrombocytopenic purpura (TTP), according to a s

  • Blood Disease
  • Japan
  • United States
  • Product Initiative
  • Ablynx NV

BY SEX, 2012 (NO. ) ## Hodgkin Lymphoma in the United Kingdom ## TABLE ## ESTIMATED NUMBER OF NEW CASES OF HODGKIN LYMPHOMA IN THE U. K., 2013 (NO. ) ## TABLE ## ESTIMATED NUMBER OF DEATHS FROM HODGKIN' S LYMPHOMA IN THE U. K., 2012 (NO. ) ## FIGURE ## ESTIMATED NUMBE

  • Blood Disease
  • Cancer
  • Pathology
  • United States
  • World
  • Market challenges

Males are susceptible to this disease as they have only one X chromosome.

  • Blood Disease
  • World
  • Market Size
  • Biogen Idec Inc.
  • CSL Behring GmbH

As of 2013, THERE ARE NO BIOSIMILARS AVAILABLE TO TREAT BLOOD DISORDERS AND INFECTIOUS DISEASES.

  • Blood Disease
  • Monoclonal Antibody
  • North America
  • United States
  • Market Size
  • JUL 09, 2018: CELGENE AND ACCELERON ANNOUNCE LUSPATERCEPT ACHIEVED PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN PHASE III 'BELIEVE' STUDY IN ADULTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA

ACE-## is currently being evaluated in two Phase ## trials: one in FSHD and one in Charcot-Marie-Tooth (CMT) disease.

  • Blood Disease
  • United States
  • World
  • Product Initiative
  • Acceleron Pharma, Inc.
  • MEXICO: APHERESIS MARKET SIZE, BY PROCEDURE, 2014-2021 (USD MILLION)
  • GLOBAL THERAPEUTIC APHERESIS MARKET SIZE, BY PROCEDURE, 2014-2021, (USD MILLION)

S. ##. ##. ##. ## The FDA approves apheresis blood collection devices intended for the collection of certain blood components only.

  • Blood Disease
  • North America
  • United States
  • World
  • Market Size
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Product Development Milestones
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Product Development Milestones

Polycythemia Vera is a rare blood disease characterized by an increased number of red blood cells, white blood cells and platelets, which significantly raises the risk for thromboembolic and hemorrhagic complications.

  • Blood Disease
  • Therapy
  • Vaccine
  • United States
  • Merck & Co., Inc.
  • Clinical Trials

Enrollment and treatment are ongoing in Part ## of the Phase ## trial in patients with CMT disease.

  • Blood Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Acceleron Pharma, Inc.

PT/ ##:## p. m.

  • Blood Disease
  • Clinical Trial
  • Point Of Care Testing
  • Rapid Test
  • Helena Laboratories Corporation
  • CLINICAL TRIAL PROFILE SNAPSHOTS

One anti-drug antibody was observed for ALXN## and one for Soliris.

  • Blood Disease
  • Leukemia
  • World
  • Product Initiative
  • Alexion Pharmaceuticals, Inc.